2023-09-29T09:52:58-05:00 2022-12-31 521392008 GELMAN ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 800N BETHESDA MD 208142930 990 2022-01-01 861884515 DAVOS ALZHEIMER'S COLLABORATIVE INC DAVO 7035999617 155 EAST LANCASTER AVENUE WAYNE PA 19087 ANDREW HOLZAPFEL COO 7035999617 2023-09-29 1 ANDREW HOLZAPFEL 999009999 0 RICHARD J LOCASTRO CPA P00288314 3019519090 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z X GEORGE VRADENBURG 155 EAST LANCASTER AVENUE WAYNE PA 19087 9767900 0 X WWW.DAVOSALZHEIMERSCOLLABORATIVE.ORG X 2020 DC SEE PART III LINE 1. 3 2 0 3 0 0 14514120 9767900 0 0 0 0 0 0 14514120 9767900 343000 2919719 0 0 0 0 0 0 82100 2424999 5181467 2767999 8101186 11746121 1666714 12443051 14995945 696930 1586998 11746121 13408947 X DAC IS LEADING THE LARGEST GLOBAL RESPONSE OF ITS KIND, DRIVING SCIENTIFIC DISCOVERY AND ALIGNING HEALTH SYSTEMS TO HELP PEOPLE WORLDWIDE, INCLUDING THOSE IN LOW RESOURCED ENVIRONMENTS LEFT OUT OF PREVIOUS EFFORTS TO FIGHT ALZHEIMER'S. WE ARE COMMITTED TO TRANSFORMING ALZHEIMER'S RESEARCH, PREVENTION AND CARE THROUGH PROVEN PRIVATE-PUBLIC MODELS, SUCH AS GAVI, CEPI AND THE GLOBAL FUND. 0 0 5968731 2419719 HEALTHCARE SYSTEM PREPAREDNESS - DAC IS INVESTING TO TRANSFORM THE WAY HEALTHCARE SYSTEMS WORLDWIDE DETECT, DIAGNOSE AND TREAT ALZHEIMER'S. THE GOAL IS TO TAKE ADVANTAGE OF FUTURE INNOVATIONS TO IMPROVE THE QUALITY OF LIFE FOR PEOPLE EVERYWHERE. IN 2022, DAC CONTINUED TO ADVANCE 7 FLAGSHIP PROJECTS IN 6 COUNTRIES AS WELL AS SUPPORT AND MONITOR THE EXECUTION OF THE INITIAL GRANTS PROGRAM (12 GRANTS IN TOTAL). 840903 GLOBAL COHORTS - DAC IS BUILDING GLOBAL COHORTS TO ADVANCE UNDERSTANDING OF ALZHEIMER'S AMONG DIVERSE POPULATIONS. THIS DATA WILL PROVIDE THE FOUNDATION FOR IDENTIFYING NEW BIOMARKERS AND DEVELOPING TARGETED TREATMENTS THAT WORK FOR PEOPLE WORLDWIDE. IN 2022, DAC RECRUITED 23 COHORTS AROUND THE GLOBE. AS A BASIS TO BEGIN CONTRACTING, DAC ALSO EXECUTED A MEMORANDUM OF UNDERSTANDING (MOU) WITH A COHORT MANAGED BY AGA KHAN UNIVERSITY IN NAIROBI, KENYA. OUTREACH TO COHORTS WERE TARGETED THAT HAVE THE STRONGEST ALIGNMENT WITH THE SCIENTIFIC PLAN AND ACCESS TO THE TARGETED MEASUREMENTS. ALSO IN 2022, DAC PROVIDED A LETTER OF INTENT TO THE NATIONAL INSTITUTES ON HEALTH OUTLINING A 5-YEAR, $50M USD GRANT THAT WAS POSITIVELY REVIEWED. 661915 500000 GLOBAL CLINICAL TRIALS - DAC IS BUILDING A GLOBAL NETWORK OF CLINICAL TRIAL SITES AND A SUPPORTING TECHNOLOGY PLATFORM TO REDUCE THE COST AND TIME OF BRINGING NEW TREATMENTS TO MARKET. DAC DEVELOPED A NETWORK OF MORE THAN 30 EUROPEAN SITES ORGANIZED FOR ACCELERATING STUDIES AND IMPLEMENTING NOVEL TRIAL DESIGNS AND SECURED A PHARMACEUTICAL COMPANY SPONSOR. 7471549 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 1 20 0 1 0 0 1 SZ 0 0 0 0 0 0 0 0 0 0 X 3 2 0 1 0 0 0 0 0 1 0 0 0 1 1 1 1 1 1 0 0 0 X X X JENNIFER K SMITH 3012520563 2030 FLOWERING TREE TERRACE SILVER SPRING MD 20902 X GEORGE VRADENBURG CHAIR & PRESIDENT 20.00 X X 0 0 0 ANDREW HOLZAPFEL COO (SEE SCHEDULE O) 30.00 X X 0 0 0 FREDA LEWIS HALL TREASURER 1.00 X X 0 0 0 0 0 0 0 0 0 0 HIGH LANTERN GROUP 685 THIRD AVE 22ND FLOOR NEW YORK NY 10017 ADMIN, MARKETING, PR, AND IT 851526 PHILIP JOUNG 1260 FRONTERA WAY MILLBRAE CA 94030 COHORTS PROGRAM MANAGEMENT 172800 SUSAN B OLIVER CONSULTING 40994 TELSA COURT WATERFORD VA 20197 MEDIA RELATIONS/MARKETING 154000 DECISION ALTERNATIVES COLLABORATIVE 5307 RANDOLPH CRESCENT DRIVE CARMEL IN 46033 HEALTHCARE SYSTEMS PROGRAM SUPPORT 134522 RHODA AU 18 REDINGTON RIDGE BOXFORD MA 01921 COHORTS PROGRAM SUPPORT 120000 6 9767900 493900 9767900 9767900 0 0 0 X 1829209 1829209 1090510 1090510 851527 787114 63795 618 275339 254511 20628 200 124455 115240 9125 90 3324512 3044433 277393 2686 290507 177129 40399 72979 2930 2533 385 12 214603 146651 67557 395 68761 63760 5001 10461 8787 1631 43 EQUIPMENT 12170 10223 1897 50 SUBSCRIPTION FEES 6202 5209 967 26 8101186 7471549 547537 82100 12435461 14926469 16547 7590 52929 12443051 14995945 696930 1586998 696930 1586998 X 11146121 12756730 600000 652217 11746121 13408947 12443051 14995945 X 1666714 -3888 X 0 1 X 1 0 X 14514120 9767900 24282020 14514120 9767900 24282020 18021800 6260220 24282020 X FORM 990, SCHEDULE A, PART II, LINE 1 THE ORGANIZATION'S EXEMPTION WAS GRANTED ON 1/12/2021 MAKING 2021 A SHORT-YEAR. THEREFORE, THE 2021 COLUMN REPRESENTS A SHORT YEAR. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 X 10152819 384919 384919 9767900 0 9767900 8486405 384919 300 385219 8101186 0 8101186 PART X, LINE 2: FOR THE YEAR ENDED DECEMBER 31, 2022, DAC HAS DOCUMENTED ITS CONSIDERATION OF FASB ASC 740-10, INCOME TAXES, THAT PROVIDES GUIDANCE FOR REPORTING UNCERTAINTY IN INCOME TAXES AND HAS DETERMINED THAT NO MATERIAL UNCERTAIN TAX POSITIONS QUALIFY FOR EITHER RECOGNITION OR DISCLOSURE IN THE COMBINED FINANCIAL STATEMENTS. PART XII, LINE 2D - OTHER ADJUSTMENTS: RELATED ORG. EXPENSES INCLUDED IN THE CONSOLIDATED FINANCIAL STATEMENTS, BUT EXCLUDED FROM PART IX OF THE FORM 990. 300. 1 NORTH AMERICA 0 15 PROGRAM SERVICES PROJECT PLANNING, REVIEW AND APPROVE AGREEMENTS WITH DAC PARTNERS, ENSURES TEAM COMMUNICATION, ENSURES TEAM HAS ACCESS TO NECESSARY DATA, TECHNOLOGY AND EQUIPMENT, MAINTAINS RECORDS. 150369 NORTH AMERICA 0 0 GRANTS TO RECIPIENTS IN THE REGION 175391 SUB-SAHARAN AFRICA 0 0 GRANTS TO RECIPIENTS IN THE REGION 90063 RUSSIA AND NEIGHBORING STATES 0 0 GRANTS TO RECIPIENTS IN THE REGION 119880 EAST ASIA AND THE PACIFIC 0 0 GRANTS TO RECIPIENTS IN THE REGION 45629 CENTRAL AMERICA AND THE CARIBBEAN 0 1 PROGRAM SERVICES RESEARCH SITE 185400 EUROPE (INCLUDING ICELAND & GREENLAND) 0 3 ADMINISTRATIVE SERVICES PERFORM NECESSARY LEGAL AND ACCOUNTING SERVICES FOR DAC SWITZERLAND; CREATE REPORT ON EU SUPPORT FOR DAC; AND CONFERENCE SPONSORSHIP. 56572 EUROPE (INCLUDING ICELAND & GREENLAND) 0 9 PROGRAM SERVICES TRAVEL AND LODGING TO CONFERENCES; RESEARCH SITE 167318 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANTS TO RECIPIENTS IN THE REGION 574250 0 28 0 0 0 28 990622 574250 1564872 NORTH AMERICA SCIENTIFIC RESEARCH FOR ALZHEIMER'S 175391 WIRE TRANSFER 0 SUB-SAHARAN AFRICA SCIENTIFIC RESEARCH FOR ALZHEIMER'S 90063 WIRE TRANSFER 0 RUSSIA AND NEIGHBORING STATES SCIENTIFIC RESEARCH FOR ALZHEIMER'S 119880 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC SCIENTIFIC RESEARCH FOR ALZHEIMER'S 15629 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC SCIENTIFIC RESEARCH FOR ALZHEIMER'S 30000 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) SCIENTIFIC RESEARCH FOR ALZHEIMER'S 74250 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) SCIENTIFIC RESEARCH FOR ALZHEIMER'S 500000 WIRE TRANSFER 0 7 0 1 0 0 0 0 0 PART I, LINE 2: GRANTEE PROVIDES WRITTEN REPORTS AT DESIGNATED TIMES OR MILESTONES. DAC PROVIDES A SAMPLE REPORT FOR GRANTEES TO USE UNLESS OTHERWISE SPECIFIED. GRANTEES ARE REQUIRED TO PARTICIPATE IN DAC FORUMS AND PROGRAMS. GRANTEE PROVIDES DAC WITH A ROYALTY-FREE LICENSE OR OTHER PERMISSION/AUTHORIZATION NECESSARY FOR DAC TO PUBLISH INSIGHTS AND KEY FINDINGS RESULTING FROM THE PROJECT, AS SHARED WITH DAC AND THE FORUMS AND PROGRAMS (ALL IN AGGREGATE OR SUMMARY FORM). GRANTEE WILL MAINTAIN COMPLETE AND ACCURATE RECORDS OF RECEIPTS AND EXPENDITURES CHARGED AGAINST THE GRANT THAT ARE SUFFICIENTLY DETAILED TO IDENTIFY THE USE OF FUNDS IN COMPLIANCE WITH THE GRANT AGREEMENT. DAC REPRESENTATIVES REVIEW THESE RECORDS AND THE RECORDS ARE TO BE MAINTAINED FOR A MINIMUM OF 3 YEARS AFTER THE COMPLETION OF THE GRANT. PART III ACCOUNTING METHOD: 1 ADVOCATE AURORA HEALTH 3075 HIGHLAND PARKWAY DOWNERS GROVE IL 60515 362167779 501(C)(3) 124911 0 SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE AVANT INSTITUTE 9835 MONROE ROAD CHARLOTTE NC 28270 822461468 64644 0 SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE INSTITUTE FOR HEALTHCARE IMP 53 STATE STREET 18TH FLOOR BOSTON MA 02109 383017223 501(C)(3) 522694 0 SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE PHYSICIAN ASSOCIATE FOUNDA 2318 MILL ROAD SUITE 1300 ALEXANDRIA VA 22314 541071370 501(C)(3) 859938 0 SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE UNIVERSITY OF WASHINGTON 4333 BROOKLYN AVENUE NE SEATTLE WA 98195 916001537 501(C)(3) 250177 0 SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE 4 1 PART I, LINE 2: GRANTEE PROVIDES WRITTEN REPORTS AT DESIGNATED TIMES OR MILESTONES. DAC PROVIDES A SAMPLE REPORT FOR GRANTEES TO USE UNLESS OTHERWISE SPECIFIED. GRANTEES ARE REQUIRED TO PARTICIPATE IN DAC FORUMS AND PROGRAMS. GRANTEE PROVIDES DAC WITH A ROYALTY-FREE LICENSE OR OTHER PERMISSION/AUTHORIZATION NECESSARY FOR DAC TO PUBLISH INSIGHTS AND KEY FINDINGS RESULTING FROM THE PROJECT, AS SHARED WITH DAC AND THE FORUMS AND PROGRAMS (ALL IN AGGREGATE OR SUMMARY FORM). GRANTEE WILL MAINTAIN COMPLETE AND ACCURATE RECORDS OF RECEIPTS AND EXPENDITURES CHARGED AGAINST THE GRANT THAT ARE SUFFICIENTLY DETAILED TO IDENTIFY THE US OF FUNDS IN COMPLIANCE WITH THE GRANT AGREEMENT. DAC REPRESENTATIVES AUDIT THESE RECORDS AND THE RECORDS ARE TO BE MAINTAINED FOR A MINIMUM OF 3 YEARS AFTER THE COMPLETION OF THE GRANT. X MEDICAL TESTS 3 493900 FMV 0 0 0 0 PART I, COLUMN (B): THE NUMBER IN COLUMB (B) REPRESENTS THE NUMBER OF CONTRIBUTIONS. FORM 990, PART VI, SECTION A, LINE 3 THE DAVOS ALZHEIMERS COLLABORATIVE, INC. (DAC) RETAINED AN INDEPENDENT CONTRACTOR, HIGH LANTERN GROUP, LLC (HLG), TO PROVIDE A SUITE OF MANAGEMENT SERVICES AND ADMINISTRATIVE SUPPORT, AS WELL AS THOSE DUTIES CUSTOMARILY PERFORMED BY AN ORG. CHAIR/PRESIDENT AND COO. DAC COMPENSATED HLG $851,526 FOR THOSE SERVICES. THE DUTIES OF THE CHAIR/PRESIDENT AND COO WERE PROVIDED TO DAC BY GEORGE VRADENBURG AND ANDREW HOLZAPFEL, RESPECTIVELY. OF THE $851,526 COMPENSATION PAID TO HLG BY DAC, $69,780 IS RELATED TO THE SERVICES PROVIDED BY ANDREW HOLZAPFEL. GEORGE VRADENBURG DOES NOT RECEIVE ANY SALARY OR PAYMENT. FORM 990, PART VI, SECTION A, LINE 8B THE ORGANIZATION HAS NO COMMITTEE WITH THE AUTHORITY TO ACT ON BEHALF OF THE BOARD. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 WAS PREPARED BY THE OUTSIDE ACCOUNTANTS. THE 990 WAS THEN REVIEWED WITH DAC'S COO AND CHAIR/PRESIDENT WITH THE AUDITORS. IT WAS THEN SHARED WITH THE BOARD AND FINALIZED UPON APPROVAL. FORM 990, PART VI, SECTION B, LINE 12C ALL OFFICERS, DIRECTORS OR TRUSTEES AND KEY EMPLOYEES(CONTRACTORS) ARE REQUIRED TO SIGN THE CONFLICT OF INTEREST POLICY AT THE FIRST BOARD MEETING OF THE YEAR AND UPON CONTRACTING OR DATE OF HIGHER. IF A CONFLICT OF INTEREST IS FOUND, THE MATTER IS PRESENTED TO THE BOARD. THE APPLICABLE INTERESTED PERSON MAKES A PRESENTATION AT THE BOARD MEETING, BUT AFTER THE PRESENTATION, HE OR SHE REFRAINS FROM VOTING OR OTHERWISE ATTEMPTING TO EXERT ANY INFLUENCE ON WHETHER THE CORPORATION SHOULD PARTICIPATE OR NOT PARTICIPATE IN SUCH TRANSACTION AND LEAVES THE MEETING DURING THE DISCUSSION OF, AND VOTE ON, THE TRANSACTION OR ARRANGEMENT INVOLVING THE POSSIBLE CONFLICT OF INTEREST. AFTER EXERCISING DUE DILIGENCE, THE BOARD DETERMINES WHETHER THE CORPORATION CAN OBTAIN WITH REASONABLE EFFORTS A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. IF A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT IS NOT REASONABLY POSSIBLE UNDER CIRCUMSTANCES NOT PRODUCING A CONFLICT OF INTEREST, THE BOARD DETERMINES BY A MAJORITY VOTE OF THE DISINTERESTED DIRECTORS WHETHER THE TRANSACTION OR ARRANGEMENT IS IN THE CORPORATION'S BEST INTEREST, WHETHER IT IS FAIR, REASONABLE, AND THE RESULT OF ARM'S-LENGTH BARGAINING, AND WHETHER IT REFLECTS REASONABLE INVESTMENT CRITERIA OR PAYMENTS FOR GOODS AND SERVICES, FURTHERS THE CORPORATION'S PURPOSES AND DOES NOT RESULT IN PRIVATE INUREMENT, IMPERMISSIBLE PRIVATE BENEFIT OR AN EXCESS BENEFIT TRANSACTION. IN CONFORMITY WITH THE ABOVE DETERMINATION, THE BOARD OR COMMITTEE MAKES ITS DECISION IN WRITING AND ON THE RECORD AS TO WHETHER TO ENTER INTO THE TRANSACTION OR ARRANGEMENT. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE UPON REQUEST. FORM 990, PART IX, LINE 11G OTHER PROGRAM SERVICES: PROGRAM SERVICE EXPENSES 486,242. MANAGEMENT AND GENERAL EXPENSES 44,304. FUNDRAISING EXPENSES 429. TOTAL EXPENSES 530,975. COHORT DATA ANALYSIS: PROGRAM SERVICE EXPENSES 268,133. MANAGEMENT AND GENERAL EXPENSES 24,431. FUNDRAISING EXPENSES 237. TOTAL EXPENSES 292,801. MEDIA RELATIONS: PROGRAM SERVICE EXPENSES 141,026. MANAGEMENT AND GENERAL EXPENSES 12,850. FUNDRAISING EXPENSES 124. TOTAL EXPENSES 154,000. HEALTHCARE SYSTEM: PROGRAM SERVICE EXPENSES 123,189. MANAGEMENT AND GENERAL EXPENSES 11,224. FUNDRAISING EXPENSES 109. TOTAL EXPENSES 134,522. PROGRAM CONSULTING: PROGRAM SERVICE EXPENSES 322,158. MANAGEMENT AND GENERAL EXPENSES 29,353. FUNDRAISING EXPENSES 284. TOTAL EXPENSES 351,795. MILESTONE RESEARCH: PROGRAM SERVICE EXPENSES 914,452. MANAGEMENT AND GENERAL EXPENSES 83,320. FUNDRAISING EXPENSES 807. TOTAL EXPENSES 998,579. PROGRAM RESEARCH: PROGRAM SERVICE EXPENSES 789,233. MANAGEMENT AND GENERAL EXPENSES 71,911. FUNDRAISING EXPENSES 696. TOTAL EXPENSES 861,840. FORM 990, PART XI, LINE 9: CURRENCY EXCHANGE LOSS -3,888. DAVOS ALZHEIMER'S COLLABORATIVE (GENEVE) COURS DE RIVE 13 C/O PESTALOZZI AV GENEVE SZ 1204 PROMOTE HEALTH BY DEVELOPING RESEARCH ON BRAIN HEALTH. SZ N/A N/A DAC 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0